DiaSorin S.p.A.. (4/21/17). "Press Release: DiaSorin Receives Authorization for the Distribution of Zika IgM Test in Europe". Saluggia.

	Region	EU (European Union)
	Organisation	DiaSorin S.p.A. (FTSE Italia Mid Cap: DIA)
	Group	DiaSorin (Group)
	Organisation 2	EU (govt)
	Product	Liaison® XL Zika Capture IgM assay
	Product 2	Liaison XL analyzer
	Person	Fava, Riccardo (DiaSorin 201607 IR + Corporate Communications Director)
	Person 2	Di Terlizzi, Ines (DiaSorin 201607 Investor Relations)

DiaSorin (FTSE Italia Mid Cap: DIA) is pleased to announce that it has received the authorization for the distribution of LIAISON® XL Zika Capture IgM assay in Europe.

After the Emergency Use Authorization (EUA) received in the United States some weeks ago, DiaSorin will also now start to distribute the Zika IgM test in Europe.

LIAISON® XL Zika Capture IgM assay is the first-of-its-kind fully-automated serology assay for the detection of Zika virus infections.

The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis, or red eyes. The illness usually is mild with symptoms lasting for several days to a week. People typically do not get sick enough to require hospitalization and they very rarely die of Zika: however, the virus infection during pregnancy can cause a serious birth defect called microcephaly, as well as other severe fetal brain defects.

Funding for the LIAISON® XL Zika Capture IgM assay was provided by the U.S. Department of Health and Human Services, which granted DiaSorin a $2.6 million contract in the fall of 2016.

About DiaSorin Group

Headquartered in Italy and listed in the FTSE Mid Cap Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the IVD “Diagnostics Specialist.”

For additional information, please contact:

Riccardo Fava
Investor Relations & Corporate Communication Senior Director
Tel: +39.0161.487988
riccardo.fava@diasorin.it

Ines Di Terlizzi
Investor Relator
Tel: +39.0161.487567
ines.diterlizzi@diasorin.it

Record changed: 2023-06-05